Long non‑coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11

Huo,Wei; Qi,Fei; Wang,Kaichen

doi:10.3892/or.2020.7680

Long non‑coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11

Authors:
- Wei Huo
- Fei Qi
- Kaichen Wang
View Affiliations

Affiliations: Department of Urology, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China, Department of Surgery, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: July 7, 2020 https://doi.org/10.3892/or.2020.7680
Pages: 1233-1245

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is a serious threat to men's health worldwide. While previous studies have demonstrated that long non‑coding RNAs (lncRNAs) are closely associated with the initiation and development of several types of cancer, the role of lncRNAs in the progression of prostate cancer remains incompletely understood. In the present study, the lncRNA brain cytoplasmic RNA 1 (BCYRN1) was found to be overexpressed in prostate tumors compared with healthy tissues. Furthermore, the expression of BCYRN1 was found to be associated with Gleason score and lymph node metastasis. It was demonstrated that BCYRN1 silencing using small interfering RNA (siRNA) inhibited the proliferation of prostate cancer cells. The results of the present study indicated the presence of a reciprocal regulatory association between BCYRN1 and microRNA (miR)‑939‑3p. In addition, it was observed that BCYRN1 directly sponged miR‑939‑3p to upregulate histone deacetylase 11 (HDAC11) expression in prostate cancer cells. Moreover, transfection of recombinant HDAC11 reversed the inhibition of cell proliferation that was induced by BCYRN1 siRNA. A positive correlation between BCYRN1 and HDAC11 mRNA expression levels was also identified in prostate tumor and healthy tissues. Therefore, the findings of the present study may provide novel insight into the effects of lncRNAs on prostate cancer, and may enable the development of new therapeutic methods for patients with prostate cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Kaarbø M, Mikkelsen OL, Malerød L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM and Saatcioglu F: PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol. 32:11–27. 2010.PubMed/NCBI
3	Bhardwaj S and Varma S: Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel. J Oncol Pharm Pract. 24:153–155. 2018. View Article : Google Scholar : PubMed/NCBI
4	Cai Z, Wu Y, Li Y, Ren J and Wang L: BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance. Aging (Albany NY). 10:3702–3712. 2018. View Article : Google Scholar : PubMed/NCBI
5	Wang XZ, Beebe JR, Pwiti L, Bielawska A and Smyth MJ: Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res. 59:5842–5848. 1999.PubMed/NCBI
6	Chen X and Yan GY: Novel human lncRNA-disease association inference based on lncRNA expression profiles. Bioinformatics. 29:2617–2624. 2013. View Article : Google Scholar : PubMed/NCBI
7	McHugh CA, Chen CK, Chow A, Surka CF, Tran C, McDonel P, Pandya-Jones A, Blanco M, Burghard C, Moradian A, et al: The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3. Nature. 521:232–236. 2015. View Article : Google Scholar : PubMed/NCBI
8	Yang Q, Wan Q, Zhang L, Li Y, Zhang P, Li D, Feng C, Yi F, Zhang L, Ding X, et al: Analysis of LncRNA expression in cell differentiation. RNA Biol. 15:413–422. 2018. View Article : Google Scholar : PubMed/NCBI
9	Qiu M, Xu Y, Wang J, Zhang E, Sun M, Zheng Y, Li M, Xia W, Feng D, Yin R and Xu L: A novel lncRNA, LUADT1, promotes lung adenocarcinoma proliferation via the epigenetic suppression of p27. Cell Death Dis. 6:e18582015. View Article : Google Scholar : PubMed/NCBI
10	Su M, Xiao Y, Tang J, Wu J, Ma J, Tian B, Zhou Y, Wang H, Yang D, Liao QJ and Wang W: Role of lncRNA and EZH2 interaction/regulatory network in lung cancer. J Cancer. 9:4156–4165. 2018. View Article : Google Scholar : PubMed/NCBI
11	Zan XY and Li L: Construction of lncRNA-mediated ceRNA network to reveal clinically relevant lncRNA biomarkers in glioblastomas. Oncol Lett. 17:4369–4374. 2019.PubMed/NCBI
12	Du Y, Weng XD, Wang L, Liu XH, Zhu HC, Guo J, Ning JZ and Xiao CC: LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression. Oncotarget. 8:94358–94370. 2017. View Article : Google Scholar : PubMed/NCBI
13	Lingadahalli S, Jadhao S, Sung YY, Chen M, Hu L, Chen X and Cheung E: Novel lncRNA LINC00844 regulates prostate cancer cell migration and invasion through AR signaling. Mol Cancer Res. 15:1865–1878. 2018. View Article : Google Scholar
14	Gu P, Chen X, Xie R, Xie W, Huang L, Dong W, Han J, Liu X, Shen J, Huang J and Lin T: A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer. Mol Cancer. 18:1092019. View Article : Google Scholar : PubMed/NCBI
15	Shin H, Kim Y, Kim M and Lee Y: BC200 RNA: An emerging therapeutic target and diagnostic marker for human cancer. Mol Cells. 41:993–999. 2018.PubMed/NCBI
16	Wu K, Xu K, Liu K, Huang J, Chen J, Zhang J and Zhang N: Long noncoding RNA BC200 regulates cell growth and invasion in colon cancer. Int J Biochem Cell Biol. 99:219–225. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zhao RH, Zhu CH, Li XK, Cao W, Zong H, Cao XG and Hu HY: BC200 LncRNA a potential predictive marker of poor prognosis in esophageal squamous cell carcinoma patients. Onco Targets Ther. 9:2221–2226. 2016.PubMed/NCBI
18	Iacoangeli A, Adzovic L, Chen EQ, Latif Cattie R, Soff GA and Tiedge H: Regulatory BC200 RNA in peripheral blood of patients with invasive breast cancer. J Investig Med. 66:1055–1063. 2018. View Article : Google Scholar : PubMed/NCBI
19	Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, Kopp-Schneider A, Heinicke U, Fulda S, Witt Om, et al: Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell Death Dis. 8:e26352017. View Article : Google Scholar : PubMed/NCBI
20	Byun SK, An TH, Son MJ, Lee DS, Kang HS, Lee EW, Han BS, Kim WK, Bae KH, Oh KJ and Lee SC: HDAC11 inhibits myoblast differentiation through repression of MyoD-dependent transcription. Mol Cells. 40:667–676. 2017.PubMed/NCBI
21	Deubzer HE, Schier MC, Oehme I, Lodrini M, Haendler B, Sommer A and Witt O: HDAC11 is a novel drug target in carcinomas. Int J Cancer. 132:2200–2208. 2013. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Vaz CV, Alves MG, Marques R, Moreira PI, Oliveira PF, Maia CJ and Socorro S: Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. Int J Biochem Cell Biol. 44:2077–2084. 2012. View Article : Google Scholar : PubMed/NCBI
24	Pashaei E, Pashaei E, Ahmady M, Ozen M and Aydin N: Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy. PLoS One. 12:e01795432017. View Article : Google Scholar : PubMed/NCBI
25	Guo LL, Song CH, Wang P, Dai LP, Zhang JY and Wang KJ: Competing endogenous RNA networks and gastric cancer. World J Gastroenterol. 21:11680–11687. 2015. View Article : Google Scholar : PubMed/NCBI
26	Katoh H, Qin ZS, Liu R, Wang L, Li W, Li X, Wu L, Du Z, Lyons R, Liu CG, et al: FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1. Mol Cell. 44:770–784. 2011. View Article : Google Scholar : PubMed/NCBI
27	Samson J, Cronin S and Dean K: BC200 (BCYRN1)-The shortest, long, non-coding RNA associated with cancer. Noncoding RNA Res. 3:131–143. 2018. View Article : Google Scholar : PubMed/NCBI
28	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
29	Yang B, Zhang L, Cao Y, Chen S, Cao J, Wu D, Chen J, Xiong H, Pan Z, Qiu F, et al: Overexpression of lncRNA IGFBP4-1 reprograms energy metabolism to promote lung cancer progression. Mol Cancer. 16:1542017. View Article : Google Scholar : PubMed/NCBI
30	Chen S, Xu X, Lu S and Hu B: Long non-coding RNA HAND2-AS1 targets glucose metabolism and inhibits cancer cell proliferation in osteosarcoma. Oncol Lett. 18:1323–1329. 2019.PubMed/NCBI
31	Li Z, Li X, Wu S, Xue M and Chen W: Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway. Cancer Sci. 105:951–955. 2014. View Article : Google Scholar : PubMed/NCBI
32	Leslie PL, Chao YL, Tsai YH, Ghosh SK, Porrello A, Van Swearingen AED, Harrison EB, Cooley BC, Parker JS, Carey LA and Pecot CV: Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. Nat Commun. 10:41922019. View Article : Google Scholar : PubMed/NCBI
33	Bhaskara S: Histone deacetylase 11 as a key regulator of metabolism and obesity. EBioMedicine. 35:27–28. 2018. View Article : Google Scholar : PubMed/NCBI
34	Lin L, Hou J, Ma F, Wang P, Liu X, Li N, Wang J, Wang Q and Cao X: Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J Immunol. 191:3896–3904. 2013. View Article : Google Scholar : PubMed/NCBI
35	Cui C, Zhai D, Cai L, Duan Q, Xie L and Yu J: Long noncoding RNA HEIH promotes colorectal cancer tumorigenesis via counteracting miR-939 mediated transcriptional repression of Bcl-xL. Cancer Res Treat. 50:992–1008. 2018. View Article : Google Scholar : PubMed/NCBI
36	Ying X, Liya Q, Feng Z, Yin W and Ji-hong L: MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression. Biomed Pharmacother. 71:64–69. 2015. View Article : Google Scholar : PubMed/NCBI
37	Liu H, Hu Q, D'Ercole AJ and Ye P: Histone deacetylase 11 regulates oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells. Glia. 57:1–12. 2009. View Article : Google Scholar : PubMed/NCBI